AGN - Allergan plc

NYSE - Nasdaq Real Time Price. Currency in USD
166.00
-0.10 (-0.06%)
At close: 4:01PM EDT

166.00 0.00 (0.00%)
After hours: 5:12PM EDT

Stock chart is not supported by your current browser
Previous Close166.10
Open166.31
Bid165.29 x 1100
Ask166.18 x 800
Day's Range165.43 - 166.37
52 Week Range114.27 - 197.00
Volume1,362,592
Avg. Volume4,947,184
Market Cap54.464B
Beta (3Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-25.50
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & Yield2.96 (1.79%)
Ex-Dividend Date2019-08-12
1y Target Est183.07
Trade prices are not sourced from all markets
  • Establishment Labs Poised to Capitalize on Allergan Breast Implant Issues
    GuruFocus.com

    Establishment Labs Poised to Capitalize on Allergan Breast Implant Issues

    Costa Rican company’s technology believed to cause fewer complications Continue reading...

  • PR Newswire

    Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019

    In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (AGN) ("Allergan") confirms that, as of the close of business on September 16, 2019, Allergan's issued share capital, excluding treasury shares, consisted of 328,122,662 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). Allergan confirms that, as of the close of business on September 16, 2019, there were outstanding 2,827,357 restricted share units (the "Allergan Restricted Share Units") and 6,008,399 options to purchase Allergan Ordinary Shares (the "Allergan Share Options") granted by Allergan. Upon vesting, each Allergan Restricted Share Unit entitles the holder to receive one Allergan Ordinary Share and each Allergan Share Option entitles the holder to purchase one Allergan Ordinary Share at the applicable exercise price.

  • Could Algernon Pharmaceuticals Inc.'s (CNSX:AGN) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Algernon Pharmaceuticals Inc.'s (CNSX:AGN) Investor Composition Influence The Stock Price?

    The big shareholder groups in Algernon Pharmaceuticals Inc. (CNSX:AGN) have power over the company. Insiders often own...

  • PR Newswire

    Allergan Announces Commencement of Mailing of Proxy Statement

    Allergan plc (AGN) today announced, for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the "Irish Takeover Rules"), that the definitive proxy statement of Allergan (the "Proxy Statement"), which also constitutes a scheme circular under Irish law, is being sent as of September 16, 2019 to Allergan shareholders. As previously announced on June 25, 2019, AbbVie Inc. and Allergan entered into a definitive transaction agreement pursuant to which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019 (the "Acquisition").  The Acquisition will be effected by means of a "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014.

  • Allergan (AGN) Dips More Than Broader Markets: What You Should Know
    Zacks

    Allergan (AGN) Dips More Than Broader Markets: What You Should Know

    Allergan (AGN) closed at $165.56 in the latest trading session, marking a -0.35% move from the prior day.

  • Moody's

    AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's euro notes; stable outlook

    Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured euro-denominated notes offering of AbbVie Inc. ("AbbVie"). The are no changes to AbbVie's existing ratings including the Baa2 senior unsecured long-term ratings and the Prime-2 commercial paper rating. AbbVie's Baa2 rating reflects the company's large scale, high margins and robust cash flow, all supported by the lucrative Humira franchise.

  • Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
    Zacks

    Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

    Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

  • Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
    Zacks

    Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

    Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.

  • GuruFocus.com

    Seth Klarman's Favorite Health Care Stocks

    Klarman has the beaten-up sector as the second-largest in his portfolio Continue reading...

  • Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan
    Reuters

    Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

    About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc . The combination of two of the world's biggest pharmaceutical companies, which was announced in June, would feature a portfolio that includes the world's top-selling medicine - AbbVie's rheumatoid arthritis drug Humira - as well as its cancer drugs and Allergan's blockbuster wrinkle treatment, Botox, and big-selling dry eye drug Restasis.

  • Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade
    Investor's Business Daily

    Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade

    Revenue from AbbVie's inflammation treatment Humira will crash to $3 billion annually by 2025, an analyst said Thursday — but he upgraded AbbVie stock ahead of its Allergan buyout.

  • Barrons.com

    Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says

    AbbVie’s acquisition of Allergan will create a new company churning out $20 billion in free cash flow a year, and that makes it worth buying, UBS’ Navin Jacob said Thursday.

  • Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
    Zacks

    Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

    The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

  • Allergan (AGN) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Allergan (AGN) Outpaces Stock Market Gains: What You Should Know

    Allergan (AGN) closed the most recent trading day at $164, moving +1% from the previous trading session.

  • PR Newswire

    Allergan Shareholder Meetings Scheduled for October 14, 2019

    Allergan plc (AGN) announced that following a hearing today before the Irish High Court it has scheduled shareholder meetings for Monday, October 14, 2019, in connection with the proposed acquisition of Allergan by AbbVie Inc. (the "Acquisition"). As previously announced on June 25, 2019, AbbVie and Allergan entered into a definitive transaction agreement pursuant to which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019.  The Acquisition will be effected by means of a "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014.

  • The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
    Zacks

    The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

    The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

  • Reuters

    U.S. judge denies bid to dismiss claim opioids are a public nuisance

    The U.S. judge overseeing nationwide litigation concerning the opioid crisis on Monday rejected Purdue Pharma LP's effort to dismiss claims that its activities caused a public nuisance. U.S. District Judge Dan Polster in Cleveland said a reasonable jury could conclude that Purdue's alleged fraudulent marketing of opioids, for the purpose of increasing sales, caused a nuisance. Polster's decision came six weeks before the scheduled Oct. 21 trial on the impact of opioids on two Ohio counties.

  • PR Newswire

    Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

    DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (MOLN.SW), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA) for Abicipar pegol, a novel, investigational DARPin® therapy, in patients with neovascular (wet) age-related macular degeneration (nAMD). The FDA is expected to take action on the BLA mid-2020.

  • ETFs Poised to Benefit from Gene Editing Revolution
    Zacks

    ETFs Poised to Benefit from Gene Editing Revolution

    Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

  • Reuters

    UPDATE 1-Mallinckrodt to pay $24 mln in cash to settle opioid lawsuits with two Ohio counties

    Mallinckrodt plc said on Friday it had agreed to pay $24 million in cash to two counties in Ohio, to settle lawsuits related to an ongoing multidistrict opioid litigation in the United States. The development comes as opioid makers in the country face a string of lawsuits seeking to hold them responsible for fueling the opioid addiction crisis. Last month, Endo International Plc agreed to pay $10 million and Allergan Plc agreed to pay $5 million to the same two Ohio counties, Cuyahoga and Summit, to avoid going to trial in October.

  • Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
    Zacks

    Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs

    Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.

  • 3 Special Situations Gurus Are Buying
    GuruFocus.com

    3 Special Situations Gurus Are Buying

    Allergan makes the list Continue reading...

  • Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease
    Zacks

    Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease

    Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.

  • Allergan (AGN) Up 1.8% Since Last Earnings Report: Can It Continue?
    Zacks

    Allergan (AGN) Up 1.8% Since Last Earnings Report: Can It Continue?

    Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.